Free Trial
NYSE:CVM

CEL-SCI (CVM) Stock Price, News & Analysis

CEL-SCI logo
$2.50 -0.01 (-0.40%)
Closing price 04:00 PM Eastern
Extended Trading
$2.47 -0.03 (-1.24%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About CEL-SCI Stock (NYSE:CVM)

Key Stats

Today's Range
$2.35
$2.54
50-Day Range
$2.46
$9.18
52-Week Range
$2.32
$66.60
Volume
280,124 shs
Average Volume
52,995 shs
Market Capitalization
$7.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Receive CVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CEL-SCI and its competitors with MarketBeat's FREE daily newsletter.

CVM Stock News Headlines

CEL-SCI Announces Closing of Public Offering
Trump Makes Major Crypto Announcement
You Won’t Get a Second Chance at This Entry The crypto comeback isn't coming—it's already here. And one particular coin is sitting right at the center of this shift.
CEL-SCI Announces Pricing of Public Offering
CEL-SCI Announces Proposed Public Offering
See More Headlines

CVM Stock Analysis - Frequently Asked Questions

CEL-SCI's stock was trading at $11.9970 at the beginning of 2025. Since then, CVM shares have decreased by 79.2% and is now trading at $2.50.
View the best growth stocks for 2025 here
.

CEL-SCI Co. (NYSE:CVM) announced its earnings results on Thursday, August, 15th. The company reported ($4.20) EPS for the quarter, missing analysts' consensus estimates of ($3.90) by $0.30.

CEL-SCI's stock reverse split on the morning of Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Top institutional shareholders of CEL-SCI include MAI Capital Management (0.63%). Insiders that own company stock include Geert R Kersten, Patricia B Prichep and Robert Eugene Watson.
View institutional ownership trends
.

Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that CEL-SCI investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Pfizer (PFE), Canopy Growth (CGC) and Inovio Pharmaceuticals (INO).

Company Calendar

Last Earnings
8/15/2024
Today
5/28/2025
Fiscal Year End
9/30/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:CVM
Employees
43
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$26.92 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$0.15 per share
Price / Book
16.47

Miscellaneous

Free Float
64,673,000
Market Cap
$7.49 million
Optionable
Optionable
Beta
0.50
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NYSE:CVM) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners